Global biosimilars market growth is driven by rising healthcare costs worldwide and the expiration of blockbuster biologics patents. Biosimilars provide affordable treatment options for chronic diseases such as cancer, diabetes, and autoimmune disorders. These offer significant cost savings as compared to reference biologics. For example, Filgrastim’s biosimilar Zarzio was launched at a 15% lower price compared to original biologic Neupogen. Regulatory approvals for biosimilars have also increased in major markets like the U.S, EU, and Japan following clear guidelines, thus, easing market entry. This has attracted many emerging players to the large and lucrative biosimilars market.

Market Dynamics:

Global biosimilars market growth is driven by factors like rising chronic disease prevalence rates worldwide coupled with limited healthcare budgets. This has boosted demand for lower-cost biosimilar alternatives to biologics. Many blockbusters biologic drugs are expected to lose patent protection over the forecast period 2018-2026, thus, offering potential for biosimilar entrants. For instance, infliximab and adalimumab are among the highest revenue earning biologics that faced biosimilar competition by 2023. Regulatory approvals and product launches, along with marketing expansion activities by major players can drive the market growth.

Key Features of the Study:

• This report provides in-depth analysis of the global biosimilars market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global biosimilars market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Novartis, Pfizer, Teva Pharmaceuticals, Celltrion, Biocon, Amgen, Samsung Biologics, Stada Arzneimittel AG.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• Global biosimilars market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global biosimilars market.

Detailed Segmentation-

• By Drug Class
  
  • Recombinant Human Growth Hormone
  • Granulocyte Colony-Stimulating Factor
  • Insulin
  • Anticoagulants
  • Fusion Proteins Erythropoietin 
  • Monoclonal Antibodies
  • Follitropin
  • Others
• By Therapy Type
  
  • Oncology
  • Immunology
  • Hematology
  • Hormone Therapy
  • Metabolic Disorders
  • Others
•    By Distribution Channel
• • Hospital Pharmacies
  • Retail Pharmacies
  • Specialty Pharmacies
•   By Region         
• • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
• • Amgen Inc.
  • Pfizer Inc.
  • Samsung Bioepis Co., Ltd.
  • Sandoz International GmbH
  • Celltrion Healthcare Co., Ltd.
  • Biocon Limited
  • Reddy's Laboratories Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Boehringer Ingelheim International GmbH
  • Fresenius Kabi AG
  • Merck & Co., Inc.
  • Biogen Idec Inc
  • Coherus BioSciences
  • Stada Arzneimittel AG